• DOI:10.3928/01477447-20151002-59
• Corpus ID: 23276800

Frozen Autograft-Prosthesis Composite Reconstruction in Malignant Bone Tumors.

@article{Subhadrabandhu2015FrozenAC,
  title={Frozen Autograft-Prosthesis Composite Reconstruction in Malignant Bone Tumors.},
  author={Saran Subhadrabandhu and Akihiko Takeuchi and Norio Yamamoto and Toshiharu Shirai and Hideji Nishida and Katsuhiro Hayashi and Shinji Miwa and Hiroyuki Tsuchiya},
  journal={Orthopedics},
  year={2015},
  volume={38 10},
  pages={
          e911-8
        }
}

• Saran Subhadrabandhu, A. Takeuchi, +5 authors H. Tsuchiya
• Published 1 October 2015
• Medicine
• Orthopedics

Several methods are available using an endoprosthesis or biological reconstruction for malignant bone tumors. Methods that use allograft-prosthesis composites have shown promising results. In 1999, the authors developed a method of reconstruction that uses a tumor-bearing autograft treated with liquid nitrogen. This technique was modified to produce a pedicle frozen autograft to maintain anatomical continuity on one side. In this study, the results of bone reconstructions using frozen autograft-prosthesis composites were retrospectively evaluated. The demographic data, histological records, surgical procedures, functional scores, and complications of 22 patients who had bone sarcoma or metastasis and at least 2 years of follow-up were reviewed. There were 19 patients with primary bone sarcoma and 3 with bone metastasis. Average age was 36 years (range, 9-73 years), and mean follow-up was 63 months (range, 24-176 months). Reconstructions were performed on 10 proximal femurs, 5 distal femurs, 4 proximal tibias, 1 proximal humerus, 1 proximal radius, and 1 hemipelvis. There were 12 pedicle-freezing and 10 free-freezing procedures. Union rate was 90% (9/10), and average union time was 9.5 months. Average Musculoskeletal Tumor Society score was 89.3%. Complications included 1 fracture, 2 infections, 3 soft tissue recurrences, and 1 posterior interosseous nerve palsy. The authors concluded that the frozen autograft-prosthesis composite demonstrated excellent Musculoskeletal Tumor Society scores, a low complication rate, and a good union rate and was superior when used with the pedicle-freezing technique.